Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play

Why It Matters

The success of Rezdiffra validates MASH as a lucrative therapeutic area, accelerating investment, partnership and acquisition activity that could reshape liver‑disease treatment pipelines.

Key Takeaways

• Rezdiffra generated $817M revenue in six quarters
• Big Pharma spent $9.9B on FGF21 assets in 2025
• Lanifibranor Phase III readout expected H2 2026
• VK2809 showed up to 75% MASH resolution in Phase IIb
• Pemvidutide earned Breakthrough Therapy Designation for MASH

Pulse Analysis

The approval of Madrigal’s resmetirom (Rezdiffra) marked a watershed moment for metabolic dysfunction‑associated steatohepatitis, turning a historically barren field into a high‑growth market. Within a year of launch the drug posted $287 million in quarterly sales, and cumulative revenue topped $800 million, proving that effective MASH therapy can be both clinically and commercially viable. This performance sparked a strategic scramble among large pharmaceutical companies, culminating in three multi‑billion‑dollar acquisitions of FGF21 analog programs in 2025. The influx of capital not only validates the disease’s commercial potential but also raises the bar for emerging candidates seeking to capture market share.

As the FGF21 space consolidates, investors and big‑pharma executives are turning to differentiated mechanisms to sustain pipeline momentum. Inventiva’s pan‑PPAR agonist lanifibranor, poised to deliver Phase III data in late 2026, targets fibrosis, inflammation and metabolic dysregulation simultaneously. Viking’s THR‑β agonist VK2809 demonstrated up to 75 % MASH resolution in a Phase IIb trial, while Altimmune’s GLP‑1/glucagon dual agonist pemvidutide earned Breakthrough Therapy Designation after showing 52 % resolution without fibrosis worsening. Meanwhile, Sagimet’s fatty‑acid‑synthase inhibitor denifanstat is pursuing a combination strategy with Rezdiffra, aiming to amplify fibrosis reduction. Each of these assets offers a unique therapeutic angle that could attract partnership or acquisition offers.

The broader implication for the industry is a shift toward combination regimens and strategic M&A to assemble multi‑targeted portfolios. With the disease’s multifactorial nature—encompassing liver fat accumulation, inflammation, and fibrosis—single‑mode agents may struggle to achieve optimal outcomes. Big pharma’s recent spending spree suggests a willingness to integrate niche biotech innovations into larger metabolic franchises, leveraging scale for late‑stage development and global rollout. For investors, the next wave of MASH deals will likely hinge on robust Phase III readouts and the ability of candidates to complement existing therapies such as Rezdiffra and Wegovy, positioning the sector for sustained growth beyond the initial blockbuster approvals.